Ionis files Form 144 to sell 973 shares

Ionis Pharmaceuticals submitted a Form 144 notifying a proposed sale of 973 shares of Common Stock (issued as RSUs under the 2011 Equity Incentive Plan) through Morgan Stanley on 04/16/2026.

Rhea-AI Filing Summary

Ionis Pharmaceuticals submitted a Form 144 notifying a proposed sale of 973 shares of Common Stock (issued as RSUs under the 2011 Equity Incentive Plan) through Morgan Stanley on 04/16/2026. The filing lists prior share sales in the past three months: 8,480 shares sold on 01/15/2026 for $636,932.80 and 6,179 shares sold on 01/30/2026 for $513,047.87.

Insights

Securities Compliance Expert

Form 144 notifies a brokered resale of 973 RSU-derived shares.

Form 144 is a regulatory notice that a holder proposes to sell restricted or control securities through a broker. The filing here identifies 973 shares tied to RSUs under the 2011 Equity Incentive Plan and lists Morgan Stanley as the broker and 04/16/2026 as the filing date.

Prior transactions are recorded for context: 8,480 shares on 01/15/2026 and 6,179 shares on 01/30/2026, with the stated gross amounts. This notice is administrative; cash‑flow treatment and seller identity beyond the broker are not specified in the excerpt.

Key Figures

Shares proposed for sale: 973 shares RSU grant date: 04/15/2026 Prior sale 1: 8,480 shares +2 more

5 metrics

Shares proposed for sale 973 shares Form 144 filed through Morgan Stanley on 04/16/2026

RSU grant date 04/15/2026 RSUs granted under the 2011 Equity Incentive Plan

Prior sale 1 8,480 shares Sold 01/15/2026 for $636,932.80

Prior sale 2 6,179 shares Sold 01/30/2026 for $513,047.87

Stated value for 973 shares $73,362.15 Value listed alongside 973 shares on 04/16/2026 row

Key Terms

Form 144, RSU, 2011 Equity Incentive Plan

3 terms

Form 144 regulatory

"144: Securities To Be Sold Common Stock | 04/15/2026"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU financial

"RSUs granted under 2011 Equity Incentive Plan | Ionis Pharmaceuticals"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

2011 Equity Incentive Plan regulatory

"RSUs granted under 2011 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ionis's Form 144 for 973 shares mean?

It notifies a proposed brokered resale of 973 Common Stock shares issued as RSUs under the 2011 Equity Incentive Plan, filed with Morgan Stanley on 04/16/2026. It is a regulatory notice, not a confirmation of sale completion.

Who is the broker listed on the Ionis (IONS) Form 144?

The filing lists Morgan Stanley Smith Barney at 1585 Broadway, New York, as the broker. The notice indicates Morgan Stanley handled prior transactions and is the broker of record for the proposed sale.

What prior sales does the Form 144 disclose for IONS?

The notice records sales in the past three months: 8,480 shares sold on 01/15/2026 for $636,932.80, and 6,179 shares sold on 01/30/2026 for $513,047.87. These are listed as recent dispositions.

Are the 973 shares from new grants or previously vested awards?

The filing ties the 973 shares to RSUs granted under the 2011 Equity Incentive Plan with a grant date of 04/15/2026. The form indicates the shares derive from compensation-related RSUs.

Does Form 144 state who receives proceeds from the sale?

The excerpt does not specify proceeds recipients. Form 144 primarily notifies a proposed resale through a broker; it does not, in this excerpt, state who will receive the cash from any completed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 06:47 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001970151
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Birchler Brian
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	973	73362.15	165192011	04/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	04/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			973	04/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/15/2026	8480	636932.80
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/30/2026	6179	513047.87

144: Remarks and Signature

Remarks
Date of Notice	04/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Birchler
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)